Seeking Alpha

Tonix Pharmaceuticals Reports Second Quarter 2024 Financial Results and Operational Highlights

On track to submit NDA in second half 2024 for TNX-102 SL for fibromyalgia; completed successful pre-NDA meetings with FDA in second quarter 2024 FDA granted Fast Track designation for TNX-102 SL for ...
Seeking Alpha

Tonix Pharmaceuticals Announces Selection of Two Contract Manufacturing Organizations for the Launch and Commercial Manufacture of Tonmya™ for the Management of Fibromyalgia

CHATHAM, N.J., March 20, 2024 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (TNXP) (Tonix or the Company), a biopharmaceutical company with marketed products and a pipeline of development ...
FOX8 Cleveland

Tonix Pharmaceuticals Announces U.S. Commercial Availability of TONMYA™ (cyclobenzaprine HCl sublingual tablets) as a First-in-Class Fibromyalgia Treatment

TONMYA is a unique, non-opioid, once-daily bedtime analgesic that significantly reduces fibromyalgia pain and is generally well-tolerated CHATHAM, N.J., Nov. 17, 2025 (GLOBE NEWSWIRE) -- Tonix ...
Forbes

New Therapeutic Promise For Fibromyalgia

Forbes contributors publish independent expert analyses and insights. Greg Licholai writes and teaches about innovation in healthcare. This month you might see the purple colors of Fibromyalgia ...